Publikationen

Ludwig, H., Melchardt, T., Sormann, S., Schreder, M., Andel, J., Hartmann, B., Tinchon, C., Zojer, N., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Wöll, E., Ruckser, R., Bozic, B., Krauth, M., Petzer, A., Schmitt, C., Machherndl-Spandl, S., Agis, H., Fillitz, M., Wang, S., Zabernigg, A., Knop, S., Paiva, B., & Greil, R. (2024). Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma. American Journal of Hematology, 99(5), 1008-1011.

Kafka, M., Giannini, G., Artamonova, N., Neuwirt, H., Ofner, H., Kramer, G., Bauernhofer, T., Luger, F., Höfner, T., Loidl, W., Griessner, H., Lusuardi, L., Bergmaier, A., Berger, A., Winder, T., Weiss, S., Bauinger, S., Krause, S., Drerup, M., Heinrich, E., Schneider, M., Madersbacher, S., Vallet, S., Stoiber, F., Laimer, S., Hruby, S., Schachtner, G., Nagele, U., Lenart, S., Ponholzer, A., Pfuner, J., Wiesinger, C., Kamhuber, C., Müldür, E., Bektic, J., Horninger, W., & Heidegger, I. (2024). Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer. Clinical Genitourinary Cancer, 22(2), 458-466.e1.

Strassl, I., & Podar, K. (2024). The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma. Expert Opinion on Drug Discovery, 19(4), 377-391.

Pencik, J., Philippe, C., Schlederer, M., Atas, E., Pecoraro, M., Grund-Gröschke, S., Li, W. J., Tracz, A., Heidegger, I., Lagger, S., Trachtová, K., Oberhuber, M., Heitzer, E., Aksoy, O., Neubauer, H. A., Wingelhofer, B., Orlova, A., Witzeneder, N., Dillinger, T., Redl, E., Greiner, G., D'Andrea, D., Östman, J. R., Tangermann, S., Hermanova, I., Schäfer, G., Sternberg, F., Pohl, E. E., Sternberg, C., Varady, A., Horvath, J., Stoiber, D., Malcolm, T. I., Turner, S. D., Parkes, E. E., Hantusch, B., Egger, G., Rose-John, S., Poli, V., Jain, S., Armstrong, C. W. D., Hoermann, G., Goffin, V., Aberger, F., Moriggl, R., Carracedo, A., McKinney, C., Kennedy, R. D., Klocker, H., Speicher, M. R., Tang, D. G., Moazzami, A. A., Heery, D. M., Hacker, M., & Kenner, L. (2023). STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway. Molecular Cancer, 22(1), 133.

Pleyer, L., Vaisband, M., Drost, M., Pfeilstöcker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Pichler, A., Hartmann, B., Petzer, A., Schreder, M., Schmitt, C. A., Vallet, S., Melchardt, T., Zebisch, A., Pichler, P., Zaborsky, N., Machherndl-Spandl, S., Wolf, D., Keil, F., Hasenauer, J., Larcher-Senn, J., & Greil, R. (2023). Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT. American Journal of Hematology, 98(11), 1685-1698.

Podar, K. (2023). Targeting mtDAMPed macrophages for MM therapy. Blood, 141(25), 3012-3014.

Benda, M. A., Ulmer, H., Weger, R., Reimann, P., Lang, T., Pichler, P., Winder, T., Hartmann, B., Strassl, I., Krauth, M. T., Agis, H., Sormann, S., Podar, K., Willenbacher, W., & Willenbacher, E. (2023). Attrition Rates in Multiple Myeloma Treatment under Real World Conditions. Cancers, 15(3), 962.

Wirth, S. R. M., Podar, K., Pecherstorfer, M., Wohlfarth, P., Jaeger, U., & Singer, J. (2023). Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study. Cancers, 15(2), 524.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y. T., Chauhan, D., Mitsiades, C., Prabhala, R., Raje, N., Anderson, K. C., Stover, D. R., & Munshi, N. C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.